[
  {
    "ts": null,
    "headline": "BlackRock Sustainable Advantage Large Cap Core Fund Q4 2024 Commentary",
    "summary": "BlackRock Sustainable Advantage Large Cap Core Fund posted returns of 1.60% (Institutional shares) and 1.57% (Investor A shares, without sales charge) for the fourth quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=81ed80b35c2aa6c1731852b8ead63a26ca239cc0945337c24fa8eb9e46e858d5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742767140,
      "headline": "BlackRock Sustainable Advantage Large Cap Core Fund Q4 2024 Commentary",
      "id": 133333236,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367307622/image_1367307622.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Sustainable Advantage Large Cap Core Fund posted returns of 1.60% (Institutional shares) and 1.57% (Investor A shares, without sales charge) for the fourth quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=81ed80b35c2aa6c1731852b8ead63a26ca239cc0945337c24fa8eb9e46e858d5"
    }
  },
  {
    "ts": null,
    "headline": "Lantheus Holdings: One Blockbuster, Evolving Pipeline",
    "summary": "Lantheus Holdings' stock surges on strong Q4, driven by Pylarify's $1B revenue and strategic growth moves.",
    "url": "https://finnhub.io/api/news?id=a3126d18c4cae3ec4842ad6bcce6aa2d5395bae189a613bc8669764c71f80a5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742731206,
      "headline": "Lantheus Holdings: One Blockbuster, Evolving Pipeline",
      "id": 133330419,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1165574706/image_1165574706.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Lantheus Holdings' stock surges on strong Q4, driven by Pylarify's $1B revenue and strategic growth moves.",
      "url": "https://finnhub.io/api/news?id=a3126d18c4cae3ec4842ad6bcce6aa2d5395bae189a613bc8669764c71f80a5d"
    }
  },
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Eli Lilly and Company (LLY)?",
    "summary": "We recently published a list of Was Jim Cramer Right About These 23 Stocks?. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed 12 months ago. During the latest episode of Mad Money, Jim Cramer advised his viewers to […]",
    "url": "https://finnhub.io/api/news?id=5590774e3746977ddd406e5499ce5a0743b1ec4f6dc29a167fda08fd2a28235e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742729170,
      "headline": "Was Jim Cramer Right About Eli Lilly and Company (LLY)?",
      "id": 133337775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Was Jim Cramer Right About These 23 Stocks?. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed 12 months ago. During the latest episode of Mad Money, Jim Cramer advised his viewers to […]",
      "url": "https://finnhub.io/api/news?id=5590774e3746977ddd406e5499ce5a0743b1ec4f6dc29a167fda08fd2a28235e"
    }
  },
  {
    "ts": null,
    "headline": "Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly",
    "summary": "It's hard to overstate how much demand could be out there for effective weight management drugs.  The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new report from Research and Markets, sales could swell to $104.9 billion by 2035.  Novo Nordisk (NYSE: NVO) markets the top-selling GLP-1 drug at the moment, but it has been losing market share to tirzepatide, a drug that Eli Lilly (NYSE: LLY) started marketing for weight management in 2023 under the brand name Zepbound.",
    "url": "https://finnhub.io/api/news?id=c48ad38cae0b4ce2fad99ec12eef07c3f4e515196b6ca82acefdfab1948e9d8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742719380,
      "headline": "Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly",
      "id": 133324402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It's hard to overstate how much demand could be out there for effective weight management drugs.  The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new report from Research and Markets, sales could swell to $104.9 billion by 2035.  Novo Nordisk (NYSE: NVO) markets the top-selling GLP-1 drug at the moment, but it has been losing market share to tirzepatide, a drug that Eli Lilly (NYSE: LLY) started marketing for weight management in 2023 under the brand name Zepbound.",
      "url": "https://finnhub.io/api/news?id=c48ad38cae0b4ce2fad99ec12eef07c3f4e515196b6ca82acefdfab1948e9d8f"
    }
  }
]